CN102293754B - 一种甲泼尼龙琥珀酸钠冻干粉针剂及其制备方法 - Google Patents
一种甲泼尼龙琥珀酸钠冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN102293754B CN102293754B CN2011102440178A CN201110244017A CN102293754B CN 102293754 B CN102293754 B CN 102293754B CN 2011102440178 A CN2011102440178 A CN 2011102440178A CN 201110244017 A CN201110244017 A CN 201110244017A CN 102293754 B CN102293754 B CN 102293754B
- Authority
- CN
- China
- Prior art keywords
- freeze
- temperature
- methylprednisolone
- injectable powder
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 41
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 25
- 238000002347 injection Methods 0.000 title abstract description 7
- 239000007924 injection Substances 0.000 title abstract description 7
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 title 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims abstract description 53
- 229960004584 methylprednisolone Drugs 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 238000004108 freeze drying Methods 0.000 claims abstract description 22
- 239000008215 water for injection Substances 0.000 claims abstract description 22
- 238000001035 drying Methods 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 26
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 24
- 238000000859 sublimation Methods 0.000 claims description 21
- 230000008022 sublimation Effects 0.000 claims description 21
- 239000001384 succinic acid Substances 0.000 claims description 14
- 229920005549 butyl rubber Polymers 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 3
- 230000000630 rising effect Effects 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 238000005303 weighing Methods 0.000 description 15
- 239000007921 spray Substances 0.000 description 13
- 229960000583 acetic acid Drugs 0.000 description 11
- 239000012362 glacial acetic acid Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 238000012856 packing Methods 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 235000019800 disodium phosphate Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005496 eutectics Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940005043 methylprednisolone 125 mg Drugs 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- LSXOKPKIBHHONG-UHFFFAOYSA-N 1-chlorobutane;hydrate Chemical compound O.CCCCCl LSXOKPKIBHHONG-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940005028 methylprednisolone 500 mg Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Abstract
Description
编号 | 产品外观 |
实施例1-1 | 白色疏松块状物,无喷瓶现象 |
实施例1-2 | 白色疏松块状物,无喷瓶现象 |
对照例1-1 | 存在喷瓶现象,少部分制剂上部瓶壁附着有制品 |
对照例1-2 | 存在喷瓶现象,少部分制剂上部瓶壁附着有制品 |
对照例2-1 | 存在喷瓶现象,少部分制剂上部瓶壁附着有制品 |
对照例2-2 | 存在喷瓶现象,少部分制剂上部瓶壁附着有制品 |
对照例3-1 | 白色疏松块状物 |
对照例3-2 | 白色疏松块状物 |
对照例4-1 | 存在喷瓶现象,大部分制剂上部瓶壁附着有制品 |
对照例4-2 | 存在喷瓶现象,大部分制剂上部瓶壁附着有制品 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102440178A CN102293754B (zh) | 2011-08-24 | 2011-08-24 | 一种甲泼尼龙琥珀酸钠冻干粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102440178A CN102293754B (zh) | 2011-08-24 | 2011-08-24 | 一种甲泼尼龙琥珀酸钠冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102293754A CN102293754A (zh) | 2011-12-28 |
CN102293754B true CN102293754B (zh) | 2012-11-28 |
Family
ID=45354592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011102440178A Active CN102293754B (zh) | 2011-08-24 | 2011-08-24 | 一种甲泼尼龙琥珀酸钠冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102293754B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103371978B (zh) * | 2012-04-28 | 2018-10-16 | 天津金耀集团有限公司 | 采用含乙醇溶剂制备的冻干粉针剂 |
CN103371979B (zh) * | 2012-04-28 | 2018-05-25 | 天津金耀集团有限公司 | 一种甲泼尼龙琥珀酸钠冻干粉针剂 |
CN103319559B (zh) * | 2013-06-21 | 2015-09-30 | 辽宁海思科制药有限公司 | 一种琥珀酸甲泼尼龙化合物 |
CN104546701B (zh) * | 2014-12-27 | 2018-08-10 | 云南盟生药业有限公司 | 一种甲泼尼龙琥珀酸钠溶液及其制备方法 |
CN108498468B (zh) * | 2018-05-25 | 2020-12-18 | 福安药业集团湖北人民制药有限公司 | 注射用甲泼尼龙琥珀酸钠 |
CN110420185A (zh) * | 2019-07-10 | 2019-11-08 | 西安交通大学 | 一种硫酸软骨素a纳米硒冻干粉针剂的制备工艺 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100508983C (zh) * | 2006-04-19 | 2009-07-08 | 天津药业焦作有限公司 | 甲泼尼龙琥珀酸钠冻干组合物及其制备方法 |
CN101050229A (zh) * | 2007-05-11 | 2007-10-10 | 天津市生物化学制药厂 | 一种氢化可的松琥珀酸钠的制备方法 |
-
2011
- 2011-08-24 CN CN2011102440178A patent/CN102293754B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102293754A (zh) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102293754B (zh) | 一种甲泼尼龙琥珀酸钠冻干粉针剂及其制备方法 | |
CN103751103B (zh) | 一种长效硫酸头孢喹肟注射液及其制备方法 | |
CN102302460B (zh) | 甲泼尼龙琥珀酸钠冻干粉针剂及其制备方法 | |
CN102133199A (zh) | 注射用多索茶碱冻干制剂及其制备方法 | |
CN102258531B (zh) | 一种含有环磷腺苷与葡甲胺的药物组合物及其制备方法 | |
CN101703484B (zh) | 一种地塞米松磷酸钠冻干粉针剂的制备方法 | |
CN102293755B (zh) | 两种甲泼尼龙琥珀酸钠冻干粉针剂及其制备方法 | |
CN104758261A (zh) | 淫羊藿苷plga纳米粒子及制备方法及用途 | |
CN103705447B (zh) | 一种长效盐酸头孢噻呋注射液及其制备方法 | |
CN103371979B (zh) | 一种甲泼尼龙琥珀酸钠冻干粉针剂 | |
CN103110581A (zh) | 一种紫杉醇微乳药物组合物及其制备方法 | |
CN103371978A (zh) | 采用含乙醇溶剂制备的冻干粉针剂 | |
CN100571685C (zh) | 一种罗哌卡因及其可药用盐冻干粉针剂的制备工艺 | |
CN103142513B (zh) | 一种注射用消旋2-(α-羟基戊基)苯甲酸盐冻干粉针及其制备方法 | |
CN101862319A (zh) | 一种供注射用的多西他赛组合物及其制备方法 | |
CN102743392B (zh) | 甲泼尼龙琥珀酸钠组合物 | |
CN105982866B (zh) | 一种艾普拉唑冻干组合物 | |
CN105796509A (zh) | 一种倍他米松磷酸钠冻干粉针剂的制备方法 | |
CN101536988A (zh) | 一种曲克芦丁冻干粉针剂及其制备方法 | |
CN103599080A (zh) | 一种注射用单磷酸阿糖腺苷的药用组合物 | |
CN102743342A (zh) | 一种供注射用夫西地酸钠冻干组合物 | |
CN104771369A (zh) | 一种磷酸氟达拉滨冻干粉针剂 | |
CN103239399B (zh) | 一种西罗莫司纳米混悬剂及其制备方法 | |
CN103565754B (zh) | 注射用亚叶酸钙组合物的冻干粉剂的制备方法 | |
CN104095821A (zh) | 一种脂溶性铂配合物注射用冻干制剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111228 Assignee: Tianjin Tianan Pharmaceuticals Co.,Ltd. Assignor: TIANJIN JINYAO GROUP Co.,Ltd. Contract record no.: 2013120000003 Denomination of invention: Methylprednisolone sodium succinate freeze-dried powder injection and preparation method thereof Granted publication date: 20121128 License type: Exclusive License Record date: 20130116 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Tianjin Tianan Pharmaceuticals Co.,Ltd. Assignor: TIANJIN JINYAO GROUP Co.,Ltd. Contract record no.: 2013120000003 Date of cancellation: 20131016 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111228 Assignee: TIANJIN KINGYORK PHARMACEUTICAL CO.,LTD. Assignor: TIANJIN JINYAO GROUP Co.,Ltd. Contract record no.: 2014120000073 Denomination of invention: Methylprednisolone sodium succinate freeze-dried powder injection and preparation method thereof Granted publication date: 20121128 License type: Common License Record date: 20140903 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161027 Address after: The Yellow Sea Road, Binhai New Area of Tianjin city in 300457 No. 221 Patentee after: TIANJIN KINGYORK PHARMACEUTICAL CO.,LTD. Address before: 300171, room 109, Jin Yao building, eight weft Road, Hedong District, Tianjin, 0806 Patentee before: TIANJIN JINYAO GROUP Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 221, Huanghai Road, Binhai New Area, Tianjin 300457 Patentee after: Tianjin Pharmaceutical Heping (Tianjin) Pharmaceutical Co.,Ltd. Country or region after: China Address before: No. 221, Huanghai Road, Binhai New Area, Tianjin 300457 Patentee before: TIANJIN KINGYORK PHARMACEUTICAL CO.,LTD. Country or region before: China |